Mitsubishi UFJ Asset Management Co. Ltd. Acquires 65,337 Shares of Edwards Lifesciences Corporation $EW

Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 6.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,112,601 shares of the medical research company’s stock after purchasing an additional 65,337 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.19% of Edwards Lifesciences worth $87,017,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Econ Financial Services Corp bought a new stake in Edwards Lifesciences during the second quarter worth about $889,000. Pacific Capital Partners Ltd acquired a new stake in Edwards Lifesciences in the second quarter valued at approximately $1,760,000. Arkadios Wealth Advisors acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $300,000. Mirova US LLC grew its holdings in shares of Edwards Lifesciences by 56.2% during the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock worth $229,257,000 after purchasing an additional 1,054,301 shares during the last quarter. Finally, Czech National Bank increased its position in Edwards Lifesciences by 5.8% in the 2nd quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock valued at $11,214,000 after acquiring an additional 7,917 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on EW shares. William Blair raised Edwards Lifesciences to a “strong-buy” rating in a research note on Friday, July 25th. UBS Group reiterated a “neutral” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a report on Monday, November 3rd. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price on the stock in a report on Monday, November 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. upped their target price on shares of Edwards Lifesciences from $85.00 to $90.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.39.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 1.1%

Shares of Edwards Lifesciences stock opened at $83.37 on Monday. The stock has a market capitalization of $48.38 billion, a P/E ratio of 12.00, a P/E/G ratio of 3.97 and a beta of 1.03. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The stock’s 50-day simple moving average is $77.78 and its 200 day simple moving average is $77.41. Edwards Lifesciences Corporation has a 52-week low of $64.89 and a 52-week high of $87.09.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the firm earned $0.67 EPS. Edwards Lifesciences’s revenue for the quarter was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.